- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Novaliq launches dry eye treatment study
Novaliq GmbH has announced the commencement of a phase I study for its dry eye syndrome treatment, cyclosporine solution (CyclASol), following United States and European patent approval.
Heidelberg, Germany-Novaliq GmbH has announced the commencement of a phase I study for its dry eye syndrome treatment, cyclosporine solution (CyclASol), following United States and European patent approval.
While conventional cyclosporine formulations are emulsions, according to Novaliq, its drug is the first and only 0.05% clear cyclosporine solution, and is available in multi-dose and preservative-free bottles.
The drug was developed from the company’s broad range semi-fluorinated alkane drug delivery platform, EyeSol.
“We are pleased to receive the United States and European patent, and to announce the start of phase I CyclASol study,” said Bernhard Günther, chief executive officer of Novaliq. “These are both significant new milestones for Novaliq as we build our innovative drug delivery portfolio.”
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
